Kenvue Inc. $KVUE Shares Sold by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd trimmed its position in shares of Kenvue Inc. (NYSE:KVUE) by 56.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 835,425 shares of the company’s stock after selling 1,103,432 shares during the period. UniSuper Management Pty Ltd’s holdings in Kenvue were worth $13,559,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in KVUE. AlphaCore Capital LLC increased its position in shares of Kenvue by 9.9% in the 2nd quarter. AlphaCore Capital LLC now owns 5,287 shares of the company’s stock valued at $111,000 after purchasing an additional 476 shares during the last quarter. Empirical Finance LLC grew its stake in shares of Kenvue by 1.8% during the second quarter. Empirical Finance LLC now owns 28,309 shares of the company’s stock worth $593,000 after purchasing an additional 491 shares in the last quarter. Proffitt & Goodson Inc. increased its holdings in Kenvue by 8.2% in the second quarter. Proffitt & Goodson Inc. now owns 6,831 shares of the company’s stock valued at $143,000 after buying an additional 517 shares during the last quarter. UMB Bank n.a. increased its holdings in Kenvue by 22.3% in the second quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock valued at $60,000 after buying an additional 521 shares during the last quarter. Finally, Altus Wealth Group LLC raised its stake in Kenvue by 1.7% in the second quarter. Altus Wealth Group LLC now owns 31,398 shares of the company’s stock valued at $657,000 after buying an additional 524 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.4%

NYSE:KVUE opened at $17.82 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market cap of $34.14 billion, a P/E ratio of 23.76 and a beta of 0.60. The stock’s 50 day simple moving average is $17.05 and its 200-day simple moving average is $18.15. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE) last released its earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The company had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business’s revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the business earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were given a $0.2075 dividend. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 annualized dividend and a yield of 4.7%. Kenvue’s dividend payout ratio is presently 110.67%.

Insider Activity at Kenvue

In related news, Director Jeffrey C. Smith bought 3,200,000 shares of the firm’s stock in a transaction on Friday, December 12th. The shares were bought at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the transaction, the director owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.68% of the company’s stock.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several research analyst reports. Zacks Research raised Kenvue from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. Canaccord Genuity Group reiterated a “hold” rating and issued a $15.00 price target (down from $26.00) on shares of Kenvue in a research note on Wednesday, October 29th. UBS Group reduced their price objective on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, October 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a research report on Friday, January 9th. Finally, Edward Jones cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average target price of $20.23.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.